Jing Ji Guan Cha Wang·2025-10-09 10:09Core Viewpoint - Johnson & Johnson's innovative targeted drug, Lico (Lanzetini Mesylate Tablets), has been launched online on JD Health, providing a breakthrough treatment option for patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) [1] Group 1: Product Launch - Lico is positioned as a first-line treatment in combination with Avelumab for advanced NSCLC, offering significant overall survival benefits and safety advantages [1] - The online launch on JD Health aims to enhance accessibility for a large population of lung cancer patients in China [1] Group 2: Strategic Partnership - JD Health and Johnson & Johnson Innovation Pharmaceuticals signed a strategic cooperation agreement in August, leveraging JD Health's supply chain and service capabilities [1] - The partnership will explore new product launches and academic exchanges, focusing on building a patient-centered healthcare service system [1]